Price T Rowe Associates Inc Repligen Corp Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Repligen Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,603,954 shares of RGEN stock, worth $802 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
6,603,954
Previous 7,566,093
12.72%
Holding current value
$802 Million
Previous $963 Million
14.68%
% of portfolio
0.09%
Previous 0.12%
Shares
19 transactions
Others Institutions Holding RGEN
# of Institutions
502Shares Held
58.3MCall Options Held
124KPut Options Held
679K-
Black Rock Inc. New York, NY7.57MShares$919 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$616 Million0.01% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$232 Million0.53% of portfolio
-
State Street Corp Boston, MA1.62MShares$197 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.4MShares$170 Million1.29% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $6.74B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....